Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
This grant supports investigator-initiated clinical trials to reduce cancer burden through early detection, prevention, and survivorship improvements.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | September 7, 2026 (AIDS) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | January 7, 2027 (AIDS)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports investigator-initiated clinical trials to reduce cancer burden through prevention, early detection, improved healthcare delivery, and survivorship.
Key Information: Only clinical trials meeting the NIH definition are eligible; trials of cancer diagnosis or oncologic therapy in patients are not supported.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, supports investigator-initiated clinical trials (R01 mechanism, clinical trial required) that aim to reduce the burden of cancer. The focus is on prevention, early detection, screening, interception, healthcare delivery, quality of life, and survivorship. The program is not intended for trials of cancer diagnosis or oncologic therapy in patients.
The supported trials should have the potential to improve clinical practice and/or public health and must align with the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.
Areas of Research
Relevant research areas include, but are not limited to:
- Cancer prevention and interception: Interventions to block, reverse, or delay early cancer stages, including behavioral, dietary, pharmacologic, or surgical approaches.
- Cancer screening and early detection: Studies on new or improved technologies, biomarkers, or practices for early cancer detection and risk assessment.
- Behavioral research: Interventions targeting risk behaviors (e.g., tobacco, alcohol, sun exposure), vaccine uptake, screening adherence, and psychosocial processes.
- Implementation science: Strategies to promote adoption and sustainability of evidence-based interventions in healthcare or public health settings.
- Healthcare delivery: Interventions to improve organization or delivery of cancer care, including team-based care, patient navigation, and survivorship programs.
- Cancer survivorship: Interventions to address physical, psychological, social, or financial burdens among survivors and their families.
- Supportive and palliative care: Interventions for prevention or treatment of symptoms and morbidities related to cancer and its treatment.
- Quality of life: Studies to improve patient quality of life.
Note: Observational studies and trials of cancer diagnosis or oncologic therapy in patients are not eligible under this NOFO.
